UK-based gene and cell therapy group Oxford Biomedica has sold its Windrush Court facility in Oxford to Kadans Science Partner for £60 mln (€68 mln).
UK-based gene and cell therapy group Oxford Biomedica has sold its Windrush Court facility in Oxford to Kadans Science Partner for £60 mln (€68 mln).
Real estate investor, developer and asset manager, Firethorn Trust has appointed Charlie Ingham as director of Firethorn Investment Management, its third-party investment, development and asset management services offering.